SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
NTRA

Natera, Inc. (NASDAQ:NTRA)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
424.42+13.60 (+3.31%)
 
Market cap
$61.2B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 1, 2015
Website
Market Cap61.18B+123.9%
Revenue (ttm)2.71B+37.8%
Net Income-192.35M+24.0%
EPS-1.36+28.8%
Shares Out144.14M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,535,163
Open410.29
Previous Close410.82
Day's Range409.50 - 432.83
52-Week Range181.00 - 437.41
Beta1.50
AnalystsBuy
Price Target386.00(-9.05%)
Earnings DateNov 5, 2026
Insider Score
––Not scored
NTRA Insider Score

Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.

About NTRA

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Address
13011 McCallen Pass Building A, Austin, TX, 78753, US
Market Cap
61.18 billion
Employees
6,138
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.82M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
13 Buy1 Hold0 SellAvg target $311.86 (-27.2%)

14 firms rating NTRA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From NTRA’s reported statements · Q2 2026 (trailing 12 months)

Next catalysts

Ask Barron about NTRA

1 Day
+3.31%
5 Days
+6.12%
1 Month
+3.07%
6 Months
+112.03%
1 Year
+123.89%

$NTRA stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of NTRA by members of U.S. Congress

PoliticianTypeTraded
Josh GottheimerHouse / DPurchase$1.00K – $15.00KSep 22, 2025
Josh GottheimerHouse / DPurchase$1.00K – $15.00KAug 22, 2025
Josh GottheimerHouse / DSale$1.00K – $15.00KJul 22, 2025
Josh GottheimerHouse / DPurchase$1.00K – $15.00KNov 20, 2024

Recently reported changes in NTRA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NTRA's directors and management

Net Shares Purchased by Insiders−10k−5k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NTRA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

NTRA Revenue by Segment or Geography

NTRA's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New NTRA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NTRA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in NTRA

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$1.80B
VBVanguard Morningstar Small-Cap ETF$1.27B
VBKVanguard Morningstar Small-Cap Growth ETF$708.93M
VXFVanguard Extended Market ETF$670.93M
IBBiShares Biotechnology ETF$418.83M
IWPiShares Russell Mid-Cap Growth ETF$311.72M

Estimated from each fund’s disclosed top holdings × AUM

NTRA Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for NTRA is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from NTRA’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
0
Sells
27
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.